Organization (Industry)
MannKind Corporation (United States)
ClinicalTrials.gov lists MannKind Corporation (United States) as lead sponsor of 66 trials, counting the companies grouped under it. MannKind Corporation (United States) itself has 17 active development programs and 13 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo MannKind Corporation, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers MannKind Corporation (United States) and 1 company grouped under it: 66 lead-sponsored trials (57 its own, 9 in the grouped companies) and 3 legal-entity registrations (2 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| scPharmaceuticals (United States) | 9 | 1 |
Disease areas (41)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 44 |
| Diabetes Mellitus, Type 2 | 24 |
| Diabetes Mellitus, Type 1 | 23 |
| Insulin Resistance | 8 |
| Melanoma | 5 |
Showing 5 of 41 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 4 |
| 2015 | 2 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (17)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Technosphere Insulin | Diabetes Mellitus | Phase 3 | 15 |
| Technosphere Insulin | Diabetes Mellitus, Type 1 | Phase 3 | 6 |
| HUMAN INSULIN (BIOSYNTHETIC) | Diabetes Mellitus, Type 2 | Phase 3 | 2 |
| Clofazimine Inhalation Suspension | Mycobacterium Infections, Nontuberculous | Phase 3 | 1 |
| Basal Insulin | Diabetes Mellitus, Type 2 | Phase 3 | 1 |
Showing 5 of 17 active programs.
Approved assets (13)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| HUMAN INSULIN (BIOSYNTHETIC) | 4 |
| Basal Insulin | 3 |
| Rapid-acting Insulin Analog | 2 |
| Insulin Degludec | 2 |
| Afrezza (insulin human) Inhalation Powder | 1 |
Showing 5 of 13 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 43% hit target (n=7) | 57% on time (n=7) |
Journals published in (22)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes care | 8 |
| Diabetes technology & therapeutics | 3 |
| Diabetic medicine : a journal of the British Diabetic Association | 3 |
| Diabetes therapy : research, treatment and education of diabetes and related disorders | 2 |
| Annals of behavioral medicine : a publication of the Society of Behavioral Medicine | 1 |
Showing 5 of 22 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 275 | 48 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 348,966,000 | 5,863,000 | 66,348,000 |
| 2024 | 285,504,000 | 27,588,000 | 45,893,000 |
| 2023 | 198,962,000 | -11,938,000 | 31,283,000 |
| 2022 | 99,770,000 | -87,400,000 | 19,721,000 |
| 2021 | 75,442,000 | -80,926,000 | 12,312,000 |
| 2020 | 65,144,000 | -57,240,000 | 6,248,000 |
| 2019 | 63,038,000 | -51,903,000 | 6,900,000 |
| 2018 | 27,859,000 | -86,975,000 | 8,737,000 |
| 2017 | 11,745,000 | -117,333,000 | 14,118,000 |
| 2016 | 174,758,000 | 125,664,000 | 14,917,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (28)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-24 | Private placement | 50,000,000 | Sec extracted |
| 2025-10-07 | Debt financing | 250,000,000 | Sec extracted |
| 2025-08-24 | Royalty / licensing | not disclosed | Sec extracted |
| 2025-08-24 | Debt financing | not disclosed | Sec extracted |
| 2025-08-24 | Other financing | not disclosed | Sec extracted |
Showing 5 of 28 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 8 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2008-08-26 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| MANNKIND CORPORATION | Danbury, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 44.0% | not disclosed |
Organization relationships (7)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Jaeb Center for Health Research | Co sponsors trial with | 4 |
| University of Colorado System | Co sponsors trial with | 1 |
| Rainier Clinical Research Center | Co sponsors trial with | 1 |
| Tandem Diabetes Care Inc | Co sponsors trial with | 1 |
| Atlanta Diabetes Associates | Co sponsors trial with | 1 |
Showing 5 of 7 relationships.
Latest dated events (381)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-30 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-07-24 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-29 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-05-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 381 events.
Biomarker capability evidence (40)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AICDA | Trial sponsor | Named in trial inclusion criteria |
| AICDA | Trial sponsor | Named in trial inclusion criteria |
| DPP4 | Trial sponsor | Named in trial inclusion criteria |
| F2 | Trial sponsor | Named in trial inclusion criteria |
| F3 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 40 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, clia clinical laboratory certificates, and biomarkers this organization publishes on.